Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
IgE signaling through its high-affinity receptor FcεRI is central to the pathogenesis of numerous allergic disorders. Oral inhibitors of Bruton's tyrosine kinase (BTKis), which are currently FDA-approved for the treatment of B cell malignancies, broadly inhibit the FcεRI pathway in human mast c...
-д хадгалсан:
| Үндсэн зохиолчид: | , , |
|---|---|
| Формат: | Revisão |
| Хэл сонгох: | англи |
| Хэвлэсэн: |
2024
|
| Онлайн хандалт: | https://doi.org/10.1016/j.anai.2024.03.002 |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|